In March 2025, a 6-year-old girl named Mei, who suffered from Snijders Blok-Campeau syndrome, underwent an experimental gene therapy at Xinhua Hospital in China. This therapy was developed by Qiu, a neuroscientist with a gene-therapy company, Lanqi Xintu Gene Technology. The therapy involved delivering modified viruses into Mei's spinal fluid, but the potential risks, including death, were not discussed with her parents, Jason and Linda. After the procedure, Mei developed severe symptoms, including fever and plummeting platelet levels, leading to her untimely death. The hospital faced a fine for failing to properly oversee the trial and not registering it as required by Chinese law. Following Mei's death, her parents sought accountability by submitting a complaint to the Shanghai Jiao Tong University School of Medicine, calling for a retraction and investigation into the clinical trial. This tragic case raises significant concerns about the oversight and regulation of experimental treatments in China, particularly regarding the ethical implications of unproven therapies and the communication of risks to patients and their families. The investigation by Science and Retraction Watch highlights the need for stricter regulations and transparency in gene therapy research to prevent similar tragedies in the future.